January 31, 2024

Children from marginalized groups less likely to receive screening, more likely to be referred for failed screening, less likely to establish care with a specialist Gaps in access to childhood vision screening and vision care are prevalent among historically marginalized racial and ethnic groups and socioeconomically vulnerable families, according to a research letter published online...

Severely immunocompromised individuals had greater SARS-CoV-2 evolution, higher risk for developing resistance against therapeutic mAbs The risk for prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) varies across immunosuppressive conditions, according to a study published in the Jan. 24 issue of Science Translational Medicine. Yijia Li, M.D., from Harvard Medical School in Boston, and colleagues performed...

Increases seen in suicidal thoughts, depressive or anxiety symptoms, and inattention or hyperactivity Adolescent substance use is associated with psychiatric symptoms, including suicidal thoughts, according to a research letter published online Jan. 29 in JAMA Pediatrics. Brenden Tervo-Clemmens, Ph.D., from the University of Minnesota in Minneapolis, and colleagues examined associations between commonly used substances and psychiatric...

Significant improvement seen in overall survival with pembrolizumab versus placebo and across key subgroups For patients with clear-cell renal cell carcinoma (ccRCC), overall survival (OS) is improved for those receiving pembrolizumab versus placebo at a median follow-up of about 57 months, according to a study presented at the American Society of Clinical Oncology annual Genitourinary...

A recent systematic review and meta-analysis reveals the promising efficacy and safety of combining compound glycyrrhizin with second-generation non-sedating antihistamines in treating chronic urticaria, offering a potential advancement in dermatological therapy. This innovative approach may redefine chronic urticaria management, providing new options for patients seeking more effective treatments. Compound glycyrrhizin combined with second-generation non-sedating antihistamines...

A recent observational study delved into the long-term treatment of solar urticaria, focusing on the role of omalizumab. It reveals key findings on therapeutic outcomes and response predictors, which may provide insights for the management of the condition in clinical practice.  Solar urticaria patients show a significant response to omalizumab treatment. FcεRI level is a...

Insights were gathered from a worldwide survey conducted among allergists/immunologists, revealing prescribing patterns, challenges, and effectiveness of omalizumab in treating chronic spontaneous urticaria. The study highlights the need for novel therapies and the importance of understanding global prescription trends. Omalizumab, an FDA-approved biologic for chronic spontaneous urticaria, is widely prescribed but faces global challenges in...

A recent retrospective analysis reveals that ixekizumab-induced urticaria in psoriasis patients is associated with a shorter duration of remission, suggesting a role of mast cell activation in this process. The findings emphasize the need for targeted management strategies for patients exhibiting these adverse reactions. Ixekizumab treatment in psoriasis patients may lead to urticaria and early...

A recent systematic review has uncovered disparities in clinical trial participant demographics and outcome reporting for H1-antihistamine-refractory chronic spontaneous urticaria. This analysis reveals a need for more diverse representation and standardized outcome measures in clinical trials for this condition. The review included 23 randomized clinical trials involving 2480 participants, highlighting a global increase in trials...